CURRENT ISSUE Current Issue Cover
VOL 10 NO 4 • MAY/JUNE 2019
IN THIS ISSUE

American Society of Clinical Oncology Reports on Clinical Cancer Advances

Pamela Hallquist Viale, RN, MS, CNS, ANP

Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis

Emily A. Lemke, DNP, RN, AGPCNP-BC, AOCNP®, Amishi Y. Shah, MD, Matthew Campbell, MD, and Nizar M. Tannir, MD

Diversity Awareness and Documentation Practices Among Oncology Advanced Practice Providers

Victoria Poillucci, MSN, ACNP-BC, and Christina Z. Page, MSN, RN, AOCNP®, AGPCNP-BC

Cardiac Toxicity and Anthracyclines: Mechanism, Interventions, and the Trouble With Troponin

Grace E. Thompson, MSN, AGACNP-BC, AGPCNP-BC, and Phyllis P. Wright, DNP, AGPCNP-BC, MPH

 
Section Seperator

TODAY'S NEWS

Serum MicroRNAs for the Diagnosis of Pan...

Diagnosis of pancreatic and biliary tract cancers ...

TONIC: PD-1 Blockade in Metastatic Tripl...

Clinical and translational data from the TONIC tri...

U.S. Cancer Survivors Numbered Nearly 17...

There were more than 16.9 million Americans with a...

KEYNOTE-001: 5-Year Overall Survival Wit...

Long-term follow-up of the phase I KEYNOTE-001 stu...

Toxicity With Prostate-Only vs Prostate ...

In a UK national population-based study reported i...

More News From Today More News
Section Seperator

EDITORIALS & COMMENTARY

Immuno-Oncology Combination Therapy

A number of immune checkpoint inhibitors (ICIs) have been approved by the FDA...

Breast Cancer in the Transgender Population

ES is a 41-year-old transgender male who presented to medical oncology as a referral...

Secondary Analysis Research

In secondary data analysis (SDA) studies, investigators use data collected by other researchers...

Rucaparib and Niraparib in Ovarian Cancer

Rucaparib and niraparib are two of the newest U.S. Food and Drug Administration–approved PARP inhibitors...

JADPRO Supplement: CAR T-Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy represents an exciting innovation in the treatment of cancer...

More Editorials & Commentary More Tweets
 
Section Seperator

PREVIOUS HIGHLIGHTS

MAIA Trial: Addition of Daratumumab to L...

In the phase III MAIA trial reported in The New En...

FDA Approves New Trastuzumab Biosimilar

Today, the U.S. Food and Drug Administration ...

FDA Pipeline: Designations and Reviews i...

Recently, the U.S. Food and Drug Administration (F...

Resuming Immune Checkpoint Inhibitor The...

In a retrospective multicenter study reported in t...

Patient Perceptions of Management of Can...

In a study reported in the Journal of Clinical Onc...

More Highlights More Highlights
 
Section Seperator
Section Seperator
 
 
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.